Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,797 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Renal Tumors Clear all
Recruiting Not applicable Interventional

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT07059884
View directory record Official record
Conditions
Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma
Interventions
Exercise Intervention, Telemedicine, Aerobic Exercise Intervention, Accelerometry, Questionnaire Administration, Interview, Electronic Health Record Review
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Dublin, California • Fremont, California • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 15, 2026, 4:15 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

NCT01575548
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7
Interventions
Computed Tomography, Magnetic Resonance Imaging, Pazopanib Hydrochloride, Placebo Administration, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
579
States / cities
Fairbanks, Alaska • Tucson, Arizona • Hot Springs, Arkansas + 355 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

NCT02166255
View directory record Official record
Conditions
Recurrent Melanoma, Recurrent Pancreatic Cancer, Recurrent Renal Cell Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis
Biological · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 15, 2026, 4:15 PM EDT
Not listed Phase 2 Interventional

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

NCT00301990
View directory record Official record
Conditions
Kidney Cancer
Interventions
aldesleukin, bevacizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
11
States / cities
Los Angeles, California • Maywood, Illinois • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2014 · Synced Oct 15, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

NCT04322318
View directory record Official record
Conditions
Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Scan, Carboplatin, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Ifosfamide, Irinotecan, Magnetic Resonance Imaging, Positron Emission Tomography, Radiation Therapy, Surgical Procedure, Topotecan, Transabdominal Ultrasound, Vincristine, X-Ray Imaging
Procedure · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
178
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 138 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

NCT00006384
View directory record Official record
Conditions
Kidney Cancer
Interventions
recombinant interferon alfa, semaxanib
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 20, 2011 · Synced Oct 15, 2026, 4:15 PM EDT
Terminated Phase 1 Interventional

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT04551885
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
FT516, Avelumab, Cyclophosphamide, Fludarabine, IL-2
Drug
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Minneapolis, Minnesota • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 15, 2026, 4:15 PM EDT
Not listed Phase 1 Interventional

Fluorouracil and Biological Therapy in Treating Patients With Metastatic Kidney or Colorectal Cancer

NCT00016042
View directory record Official record
Conditions
Colorectal Cancer, Kidney Cancer
Interventions
lymphokine-activated killer cells, recombinant interferon alfa, sargramostim, fluorouracil
Biological · Drug
Lead sponsor
St. Luke's Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 15, 2026, 4:15 PM EDT
Terminated Phase 2 Interventional Results available

Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer

NCT00496756
View directory record Official record
Conditions
Kidney Cancer
Interventions
Sorafenib
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years to 120 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 2 Interventional

Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228

NCT00106301
View directory record Official record
Conditions
Carcinoma, Renal Cell, Prostatic Neoplasms
Interventions
FK228 (romidepsin)
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Duarte, California • Gainesville, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2019 · Synced Oct 15, 2026, 4:15 PM EDT
Active, not recruiting Not applicable Interventional

Reduction of Allogenic Blood Transfusion in Locally Advanced Kidney Cancer

NCT04922307
View directory record Official record
Conditions
Kidney Cancer
Interventions
Blood Sparing Protocol, Standard Blood Replacement
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Tampa, Florida • Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

NCT00638898
View directory record Official record
Conditions
Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Ovarian Mixed Germ Cell Tumor, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Brain Tumor, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Neuroblastoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
busulfan, melphalan, topotecan hydrochloride, laboratory biomarker analysis, filgrastim, autologous hematopoietic stem cell transplantation, pharmacological study, autologous bone marrow transplantation
Drug · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Months to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 15, 2026, 4:15 PM EDT
Terminated Phase 1 Interventional

Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer

NCT04473781
View directory record Official record
Conditions
Stage I Renal Cell Cancer, Stage II Renal Cell Cancer
Interventions
Interstitial Radiation Therapy
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Results available

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab

NCT01307267
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell of Head and Neck, Malignant Melanoma
Interventions
PF-05082566, rituximab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
35
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 15, 2026, 4:15 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Non-Contrast Perfusion Using Arterial Spin Labeled MR Imaging for Assessment of Therapy Response in Metastatic Renal Cell Carcinoma

NCT04831138
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
MRI with ASL, ASL-MRI
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 15, 2026, 4:15 PM EDT
Terminated No phase listed Observational

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

NCT02900248
View directory record Official record
Conditions
Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Prostate Neoplasms, Kidney Neoplasms, Liver Neoplasms, Rectal Neoplasms, Hematologic Neoplasms, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Bladder Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Brain Neoplasms, Biliary Tract Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Skin Neoplasms, Melanoma, Gastric Neoplasms, Anal Neoplasms, Sarcoma
Interventions
Provider determined
Other
Lead sponsor
CureOne
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Results available

A Phase 1b Trial in Patients With Renal Cell Cancer

NCT01258348
View directory record Official record
Conditions
Metastatic Renal Cell Cancer
Interventions
Drug: LY573636-sodium, Sunitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Indianapolis, Indiana • Greenville, South Carolina • The Woodlands, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2019 · Synced Oct 15, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA

NCT06948552
View directory record Official record
Conditions
Upper Tract Urothelial Carcinoma
Interventions
5-Aminolevulinic acid Hydrochloride (Gliolan®)
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 15, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer

NCT03617913
View directory record Official record
Conditions
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8, Stage II Urethral Cancer AJCC v8, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Stage IIIB Bladder Cancer AJCC v8, Urethral Urothelial Carcinoma
Interventions
Avelumab, Cisplatin, Fluorouracil, Mitomycin, Quality-of-Life Assessment, Radiation Therapy
Drug · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 6, 2023 · Synced Oct 15, 2026, 4:15 PM EDT
Completed No phase listed Observational

Clinical and Histopathologic Characteristics of BAP1 Mutations

NCT01773655
View directory record Official record
Conditions
Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uveal Melanoma (UM), Metastatic Uveal Melanoma (UM), Renal Cell Carcinoma, Cholangiocarcinoma
Interventions
tumor specimens
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 15, 2026, 4:15 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Fernald Community Cohort -18 Year Observational Study

NCT02295085
View directory record Official record
Conditions
Cancer, Renal Failure, Diabetes, Cardiovascular Disease
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
8 Years and older
Enrollment
9,782 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1990 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 15, 2026, 4:15 PM EDT
Completed No phase listed Observational

Biomarkers in Tissue Samples From Patients With High-Risk Wilms Tumor

NCT01118078
View directory record Official record
Conditions
Clear Cell Sarcoma of the Kidney, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Rhabdoid Tumor of the Kidney, Stage I Wilms Tumor, Stage II Wilms Tumor, Stage III Wilms Tumor, Stage IV Wilms Tumor, Stage V Wilms Tumor
Interventions
DNA methylation analysis, gene expression analysis, microarray analysis, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis
Genetic · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 16 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated May 19, 2016 · Synced Oct 15, 2026, 4:15 PM EDT
Suspended Not applicable Interventional

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

NCT06391099
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Interventions
Best Practice, Biospecimen Collection, Computed Tomography, Dietary Intervention, Educational Activity, Glucose Measurement, Ketone Measurement, Questionnaire Administration
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 15, 2026, 4:15 PM EDT
Suspended Phase 2 Interventional

Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial

NCT05928806
View directory record Official record
Conditions
Advanced Renal Cell Carcinoma
Interventions
Botensilimab, Balstilimab, Ipilimumab, Nivolumab
Drug
Lead sponsor
Michael B. Atkins, MD
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
La Jolla, California • New Haven, Connecticut • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 15, 2026, 4:15 PM EDT